Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients.

Gabrielle JongeneelMarjolein J E GreuterFelice N van ErningMiriam KoopmanGeraldine R VinkCornelis J A PuntVeerle M H Coupé

Published in: Therapeutic advances in gastroenterology (2021)

Selection of stage II CC patients for chemotherapy can be improved by either including biomarker status in the selection strategy or by improving adherence to the Dutch guideline recommendations.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
randomized controlled trial
peritoneal dialysis
type diabetes
locally advanced
patient reported